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AcrA-AcrB-TolC Bacterial Efflux Pump. The tripartite efflux pump comprises a trimeric outer membrane 
channel (TolC, PDB ID 1EK9), a trimeric inner membrane transporter (AcrB, PDB ID 2GIF), and a 
periplasmic adapter protein (AcrA, PDB ID 2F1M). The AcrB transporter uses the energy of the proton 
motive force across the inner membrane to drive the efflux of small organic compounds, including many 
antibiotics, out of the cell by way of the TolC channel. Molecules selected for efflux are thought to gain 
entry to AcrB either by way of the periplasm, the inner membrane, or the cytoplasm.
Methods
Summary and Future Work
Results of Efflux Assay
How do we generate aptamers?Antibiotic resistance is more than ever one of the most contemporary challenges threatening
the health system worldwide. According to World Health Organization, previous cases of
bacterial infections - once treatable with antibiotics - can now be lethal due to the uncontrolled
misuse of these agents. One of the main triggers of bacterial resistance is the over-expression
of multi-drug resistant (MDR) efflux pumps. These pumps allow the bacterium to pump
antibiotics out of the cell and therefore desensitizes the cells to the antibacterial inhibitory effect.
Most of the efflux pumps present in Gram negative bacteria, including E. coli, are composed of
three main components: AcrB (inner membrane transporter), AcrA (periplasmic adaptor protein
bridging the three proteins together), and TolC (channel in the outer membrane). In this project,
we propose to design small chains of nucleic acids called aptamers to bind to and block the
outer membrane channel of the efflux pump, which is a protein called TolC, to impede antibiotic
resistant bacteria from effluxing antibiotics.
• We generated 108 base DNA aptamers using a whole-cell Selex methodology after eleven rounds of 
selection and we tested R5, 9, 10, and 11 ability to block the efflux  by conducting an in-vivo efflux assay. 
• Of the rounds tested , only R10 showed an increased accumulation of fluorescent ethidium bromide within 
the E. coli cells.  This activity disappeared at R11 indicating that the tenth round of selection was optimal 
and contained the most enriched pool of aptamers that can recognize and interact with the outer 
membrane channel TolC in E. coli serving as a molecular plug. We postulate that these aptamers might be 
a significant efflux pump inhibitor. 
• Future work will tackle the cloning of the aptamer of interest into E. coli plasmid followed by sequencing 
steps to identify the base sequence of the aptamer generated.
• No accumulation of ethidium bromide was noticed in rounds 5 and 9 indicating that the aptamers resulting
from these selections were unable to bind to the TolC channel and thus could not inhibit the efflux.
• The tenth round of Selex recorded an intense accumulation of ethidium bromide implying that the
aptamers selected had higher binding affinity to the outer membrane channel of the TolC pump blocked
the efflux of the ethidium bromide to the outside of the cell.
• Surprisingly, when testing round 11, no accumulation of ethidium bromide was noted. This is likely because
the efflux inhibitory activity appeared at round 10 and disappeared at round 11 implying some
amplification of non-specific aptamers after round 11.
• We postulate that excessive cycles of selection might amplify non-specific products whereas fewer cycles
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